ABSI
Absci Corporation
Set alert
11.13 USD -0.97 -8.02%
10.45 Day range 11.80
2.30 52-week range 12.10
- YTD
- +218.91%
- 1 year
- +172.13%
- Open
- 11.41
- Prev close
- 12.10
- Mkt cap
- 1.91B
- Vol
- 4.57M
- Avg vol
- 3.53M
- EPS
- -0.79
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.45
- High
- 11.80
- Forward P/E
- -16.05
- Beta
- 2.28
- Short ratio
- 8.22
- Inst. own
- 87.33%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 12, 2026
- 50-d avg
- 9.47
- 200-d avg
- 6.45
- 1y target
- 14.82
Key statistics
- Market cap
- 1.91B
- Enterprise value
- 1.88B
- Trailing P/E
- 0.00
- Forward P/E
- -16.05
- PEG ratio
- 0.00
- Price / sales
- 1223.62
- Price / book
- 7.76
- EPS (TTM)
- -0.79
- Beta
- 2.28
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 1.56M
- Revenue growth
- -46.40%
- Free cash flow
- -50.59M
- Total cash
- 201.14M
- Total debt
- 3.83M
- Return on equity
- -57.72%
- Shares outstanding
- 171.61M
- Short % of float
- 26.24%
- 50-day average
- 9.47
- 200-day average
- 6.45
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 14.82 +33.1% upside
Now 11.13
- Target (low)
- 10.00
- Target (mean)
- 14.82
- Target (high)
- 20.00
Ratings (0m) 12 11 buy · 1 hold · 0 sell
- Strong buy2
- Buy9
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 12, 2026
Expected Nov 12, 2026. Consensus EPS estimate -0.19763.
Financials — quick view
ABSI Revenue — quarterly 318.00K
ABSI Net income — quarterly -33.21M
ABSI EPS — quarterly -0.21
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2026 | Sep 30, 2026 | -0.19081 | — | — | — |
| Aug 11, 2026 | Jun 30, 2026 | -0.19102 | -0.18 | +0.01 | +5.77% |
| May 7, 2026 | Mar 31, 2026 | -0.20 | -0.19 | +0.01 | +5.00% |
| Mar 24, 2026 | Dec 31, 2025 | -0.16 | -0.23 | -0.07 | -43.75% |
| Nov 12, 2025 | Sep 30, 2025 | -0.19 | -0.20 | -0.01 | -5.26% |
| Aug 12, 2025 | Jun 30, 2025 | -0.19 | -0.24 | -0.05 | -26.32% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 29, 2026 | Jefferies | init | — | Buy |
| Oct 16, 2026 | Keybanc | main | Overweight | Overweight |
| Oct 12, 2026 | JP Morgan | main | Overweight | Overweight |
| Oct 12, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 23, 2026 | Needham | reit | Buy | Buy |
| Sep 9, 2026 | LifeSci Capital | init | — | Outperform |
About Absci Corporation
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- absci.com
News
- Jefferies Initiates Coverage On Absci with Buy Rating, Announces Price Target of $14
- Absci to Participate in Upcoming Investor Conferences
- Keybanc Maintains Overweight on Absci, Raises Price Target to $20
- Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026
- 10 Health Care Stocks With Whale Alerts In Today’s Session
- HC Wainwright & Co. Reiterates Buy on Absci, Maintains $16 Price Target
- Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday
- Critical Contrast: Absci (NASDAQ:ABSI) and Black Diamond Therapeutics (NASDAQ:BDTX)
- Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
- Absci (NASDAQ:ABSI) vs. Silence Therapeutics (NASDAQ:SLN) Head to Head Contrast
Your note
Sign in to keep a note on ABSI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BEDRICK TODD | Officer | Stock Award(Grant) | Mar 1, 2026 | 216,942 |
| BUSCH ANDREAS | Officer | Purchase | Mar 11, 2026 | 421,446 |
| JONASSON ZACHARIAH | Chief Financial Officer | Stock Award(Grant) | Mar 1, 2026 | 499,783 |
| MCCLAIN SEAN | Chief Executive Officer | Stock Award(Grant) | Mar 1, 2026 | 8,715,450 |
| MCGINNIS KAREN K | Director | Stock Award(Grant) | Jun 3, 2026 | 48,420 |
| PANGALOS MENELAS N | Director | Stock Award(Grant) | Jun 3, 2026 | 242,408 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.81% | 25,410,048 | 282.81M | Jun 29, 2026 |
| ARK Investment Management, LLC | 7.53% | 12,925,271 | 143.86M | Jun 29, 2026 |
| Blackrock Inc. | 7.09% | 12,175,302 | 135.51M | Jun 29, 2026 |
| State Street Corporation | 4.72% | 8,097,308 | 90.12M | Jun 29, 2026 |
| Ameriprise Financial, Inc. | 4.07% | 6,991,763 | 77.82M | Jun 29, 2026 |
| Redmile Group, LLC | 3.93% | 6,739,675 | 75.01M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK ETF Trust-ARK Genomic Revolution ETF | 6.17% | 10,581,097 | 117.77M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 4.68% | 8,022,967 | 89.30M | Aug 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.88% | 4,946,402 | 55.05M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.57% | 4,407,685 | 49.06M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.27% | 3,888,889 | 43.28M | Sep 29, 2026 |
| Columbia Acorn Trust-Columbia Acorn Fund | 1.68% | 2,889,066 | 32.16M | Jun 29, 2026 |